This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

• Needham analyst Ami Fadia downgraded the rating for Biogen Inc. BIIB from Buy to Hold and maintained the price target of $270. Biogen shares closed at $159.99 on Friday. See how other analysts view this stock.
• Wolfe Research analyst Jacob Lacks downgraded the rating for Matson, Inc. MATX from Outperform to Peer Perform. Matson shares closed at $160.65 on Friday. See how other analysts view this stock.
• Barclays analyst Nicholas Campanella downgraded Pinnacle West Capital Corporation PNW from Overweight to Equal-Weight and lowered the price target from $93 to $91. Pinnacle West Capital shares closed at $91.88 on Friday. See how other analysts view this stock.
• Argus Research analyst John Eade downgraded the rating for Fortive Corporation FTV from Buy to Hold. Fortive shares closed at $74.82 on Friday. See how other analysts view this stock.
• Stifel analyst Nathan Jones downgraded Curtiss-Wright Corporation CW from Buy to Hold and maintained the price target of $370. Curtiss-Wright shares closed at $358.35 on Friday. See how other analysts view this stock.

Considering buying BIIB stock? Here’s what analysts think:

Read More:

• How To Earn $500 A Month From Apple Stock